Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Name: Αlpha¹ Rigor Record — Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Item: Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Rating: 100
Author: Αlpha¹

Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Górriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 5★ (Exemplary), 0 critical, 0 high issues for “Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 8 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

No specific rigor problems surfaced by the checks that ran.

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously reported prespecified subgroup analysis of a large, randomized, double-blind, placebo-controlled trial (FLOW). All eight rigor dimensions are adequately addressed, with clear reporting of design, ethics, statistical methods, data availability, and transparency. No copyedit issues or integrity concerns were identified.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence was present. The study type is interventional (randomized controlled trial subgroup analysis). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded from scoring. The statistics verification recomputed only a subset of reported tests (6 tests, all consistent); other statistics were not machine-verified and should not be interpreted as confirmed.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 4 recomputed directly from the reported test statistics, 1 via agent-written checks.

Reporting

Eight Dimensions8 pass

The introduction cites multiple trials and meta-analyses establishing the independent benefits of both drug classes and notes the lack of direct trials on their combination. The rationale for the prespecified subgroup analysis is clearly linked to the premise. Limitations of prior work (e.g., rare combined use in prior trials) are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on GLP-1 RAs and SGLT2i, and logically justifies the need to examine their combination.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Early trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in persons with T2D and high CV risk were powered for CV outcomes as primary and kidney outcomes as secondary.”

paraphrase[Introduction, paragraph 4]

“Since the molecular mechanisms of action of both drug classes on the CV system and the kidney may be complementary and largely independent of glucose lowering, it has been speculated that the combination might further improve clinical outcomes.”

direct quote[Introduction, paragraph 5]

“There are no clinical trials that have directly examined the combination of GLP-1 RAs plus SGLT2i on major kidney and CV outcomes in participants with T2D and CKD.”